{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:14:27Z","timestamp":1795216467230,"version":"4.10.3"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>FRAX\u00ae, a simple-to-use fracture risk calculator, was first released in 2008 and since then has been used increasingly worldwide. By calculating the 10-year probabilities of a major osteoporotic fracture and hip fracture, it assists clinicians when deciding whether further investigation, for example a bone mineral density measurement (BMD), and\/or treatment is needed to prevent future fractures. In this review, we explore the literature around osteoporosis and how FRAX has changed its management. We present the characteristics of this tool and describe the use of thresholds (diagnostic and therapeutic). We also present arguments as to why screening with FRAX should be considered. FRAX has several limitations which are described in this review. This review coincides with the release of a version, FRAXplus, which addresses some of these limitations.<\/jats:p>","DOI":"10.1007\/s40618-023-02219-9","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T15:35:42Z","timestamp":1698161742000},"page":"501-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":207,"title":["An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis"],"prefix":"10.1007","volume":"47","author":[{"given":"M.","family":"Schini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lorentzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3129-4326","authenticated-orcid":false,"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"2219_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/9781119266594.ch32","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Miller PD, Watts NB (2018) Standard techniques of bone mass measurement in adults. In: Bilezikian JP (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley, New York, pp 252\u2013259. https:\/\/doi.org\/10.1002\/9781119266594.ch32"},{"key":"2219_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group (in eng). Osteoporos Int 4:368\u2013381. https:\/\/doi.org\/10.1007\/BF01622200","journal-title":"Osteoporos Int"},{"key":"2219_CR3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.shpsc.2010.10.015","volume":"41","author":"CD Wylie","year":"2010","unstructured":"Wylie CD (2010) Setting a standard for a \u201csilent\u201d disease: defining osteoporosis in the 1980s and 1990s (in eng). Stud Hist Philos Biol Biomed Sci 41:376\u2013385. https:\/\/doi.org\/10.1016\/j.shpsc.2010.10.015","journal-title":"Stud Hist Philos Biol Biomed Sci"},{"key":"2219_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/jbmr.5650100517","volume":"10","author":"AC Looker","year":"1995","unstructured":"Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Lindsay RL (1995) Prevalence of low femoral bone density in older U.S. women from NHANES III (in eng). J Bone Miner Res 10:796\u2013802. https:\/\/doi.org\/10.1002\/jbmr.5650100517","journal-title":"J Bone Miner Res"},{"key":"2219_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults (in eng). Osteoporos Int 8:468\u2013489. https:\/\/doi.org\/10.1007\/s001980050093","journal-title":"Osteoporos Int"},{"key":"2219_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-018-0510-0","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Harvey NC, Mccloskey EV (2018) A brief history of FRAX. Arch Osteoporos. https:\/\/doi.org\/10.1007\/s11657-018-0510-0","journal-title":"Arch Osteoporos"},{"key":"2219_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1503\/cmaj.070234","volume":"177","author":"A Cranney","year":"2007","unstructured":"Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD (2007) Low bone mineral density and fracture burden in postmenopausal women. Can Med Assoc J 177:575\u2013580. https:\/\/doi.org\/10.1503\/cmaj.070234","journal-title":"Can Med Assoc J"},{"key":"2219_CR8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/jbmr.2531","volume":"30","author":"JA Kanis","year":"2015","unstructured":"Kanis JA, Mccloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747\u20131753. https:\/\/doi.org\/10.1002\/jbmr.2531","journal-title":"J Bone Miner Res"},{"key":"2219_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jocd.2017.06.013","volume":"20","author":"JA Kanis","year":"2017","unstructured":"Kanis JA, Harvey NC, Johansson H, Od\u00e9n A, Mccloskey EV, Leslie WD (2017) Overview of fracture prediction tools. J Clin Densitom 20:444\u2013450. https:\/\/doi.org\/10.1016\/j.jocd.2017.06.013","journal-title":"J Clin Densitom"},{"key":"2219_CR10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan De Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the national bone health alliance working group. Osteoporos Int 25:1439\u20131443. https:\/\/doi.org\/10.1007\/s00198-014-2655-z","journal-title":"Osteoporos Int"},{"key":"2219_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/ageing\/afaa022","volume":"49","author":"Z Paskins","year":"2020","unstructured":"Paskins Z, Ong T, Armstrong DJ (2020) Bringing osteoporosis up to date: time to address the identity crisis (in eng). Age Ageing 49:329\u2013331. https:\/\/doi.org\/10.1093\/ageing\/afaa022","journal-title":"Age Ageing"},{"key":"2219_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-022-06567-9","volume":"34","author":"JA Kanis","year":"2023","unstructured":"Kanis JA, Mccloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-Hughes B, Maggi S, Reginster J-Y (2023) The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int 34:1\u20139. https:\/\/doi.org\/10.1007\/s00198-022-06567-9","journal-title":"Osteoporos Int"},{"key":"2219_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk (in eng). Bone 35:375\u2013382. https:\/\/doi.org\/10.1016\/j.bone.2004.03.024","journal-title":"Bone"},{"key":"2219_CR14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ, Pols HA, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk: a meta-analysis (in eng). Bone 35:1029\u20131037. https:\/\/doi.org\/10.1016\/j.bone.2004.06.017","journal-title":"Bone"},{"key":"2219_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, Mccloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155\u2013162. https:\/\/doi.org\/10.1007\/s00198-004-1640-3","journal-title":"Osteoporos Int"},{"key":"2219_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737\u2013742. https:\/\/doi.org\/10.1007\/s00198-004-1734-y","journal-title":"Osteoporos Int"},{"key":"2219_CR17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","volume":"16","author":"C De Laet","year":"2005","unstructured":"De Laet C, Kanis JA, Od\u00e9n A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, Mccloskey EV, Mellstrom D, Melton LJ, Meunier PJ, Pols HAP, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330\u20131338. https:\/\/doi.org\/10.1007\/s00198-005-1863-y","journal-title":"Osteoporos Int"},{"key":"2219_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1359\/jbmr.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton LJ, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, Mccloskey EV, Mellstrom D (2004) a meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893\u2013899. https:\/\/doi.org\/10.1359\/jbmr.040134","journal-title":"J Bone Miner Res"},{"key":"2219_CR19","doi-asserted-by":"publisher","first-page":"b4229","DOI":"10.1136\/bmj.b4229","volume":"339","author":"J Hippisley-Cox","year":"2009","unstructured":"Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores (in eng). BMJ 339:b4229. https:\/\/doi.org\/10.1136\/bmj.b4229","journal-title":"BMJ"},{"key":"2219_CR20","doi-asserted-by":"publisher","first-page":"e3427","DOI":"10.1136\/bmj.e3427","volume":"344","author":"J Hippisley-Cox","year":"2012","unstructured":"Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ Br Med J 344:e3427. https:\/\/doi.org\/10.1136\/bmj.e3427","journal-title":"BMJ Br Med J"},{"key":"2219_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Oden A, Johnell O, Johansson H, De Laet C et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033\u20131046. https:\/\/doi.org\/10.1007\/s00198-007-0343-y","journal-title":"Osteoporos Int"},{"key":"2219_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00198-011-1747-2","volume":"23","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Morin S, Lix LM, Johansson H, Oden A, Mccloskey E, Kanis JA (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75\u201385. https:\/\/doi.org\/10.1007\/s00198-011-1747-2","journal-title":"Osteoporos Int"},{"key":"2219_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1359\/jbmr.2004.19.6.906","volume":"19","author":"H Johansson","year":"2004","unstructured":"Johansson H, Oden A, Johnell O, Jonsson B, De Laet C, Oglesby A, Mccloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment-a test analysis. J Bone Miner Res 19:906\u2013913. https:\/\/doi.org\/10.1359\/jbmr.2004.19.6.906","journal-title":"J Bone Miner Res"},{"key":"2219_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/13697137.2021.1945027","volume":"25","author":"EV Mccloskey","year":"2022","unstructured":"Mccloskey EV, Harvey NC, Johansson H, Lorentzon M, Liu E, Vandenput L, Leslie WD, Kanis JA (2022) Fracture risk assessment by the FRAX model. Climacteric 25:22\u201328. https:\/\/doi.org\/10.1080\/13697137.2021.1945027","journal-title":"Climacteric"},{"key":"2219_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427. https:\/\/doi.org\/10.1007\/s001980170112","journal-title":"Osteoporos Int"},{"key":"2219_CR26","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s00198-017-4134-9","volume":"28","author":"M Hoff","year":"2017","unstructured":"Hoff M, Meyer HE, Skurtveit S, Langhammer A, S\u00f8gaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporos Int 28:2935\u20132944. https:\/\/doi.org\/10.1007\/s00198-017-4134-9","journal-title":"Osteoporos Int"},{"key":"2219_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6755","author":"N Dagan","year":"2017","unstructured":"Dagan N, Cohen-Stavi C, Leventer-Roberts M, Balicer RD (2017) External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records retrospective cohort study. BMJ. https:\/\/doi.org\/10.1136\/bmj.i6755","journal-title":"BMJ"},{"key":"2219_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/aje\/kwx128","volume":"187","author":"I Goldshtein","year":"2018","unstructured":"Goldshtein I, Gerber Y, Ish-Shalom S, Leshno M (2018) Fracture risk assessment with FRAX Using real-world data in a population-based Cohort from Israel (in eng). Am J Epidemiol 187:94\u2013102. https:\/\/doi.org\/10.1093\/aje\/kwx128","journal-title":"Am J Epidemiol"},{"key":"2219_CR29","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/jbmr.123","volume":"25","author":"WD Leslie","year":"2010","unstructured":"Leslie WD, Lix LM, Johansson H, Oden A, Mccloskey E, Kanis JA (2010) Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration. J Bone Miner Res 25:2350\u20132358. https:\/\/doi.org\/10.1002\/jbmr.123","journal-title":"J Bone Miner Res"},{"key":"2219_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-016-0278-z","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Od\u00e9n A, Mccloskey EV (2016) A systematic review of intervention thresholds based on FRAX. Arch Osteoporos. https:\/\/doi.org\/10.1007\/s11657-016-0278-z","journal-title":"Arch Osteoporos"},{"key":"2219_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jocd.2017.06.008","volume":"20","author":"G El-Hajj Fuleihan","year":"2017","unstructured":"El-Hajj Fuleihan G, Chakhtoura M, Cauley JA, Chamoun N (2017) Worldwide fracture prediction (in eng). J Clin Densitom 20:397\u2013424. https:\/\/doi.org\/10.1016\/j.jocd.2017.06.008","journal-title":"J Clin Densitom"},{"key":"2219_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, Mccloskey E, Bruy\u00e8re O, Veronese N et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312. https:\/\/doi.org\/10.1007\/s00198-019-05176-3","journal-title":"Osteoporos Int"},{"key":"2219_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00198-017-4341-4","volume":"29","author":"P Clark","year":"2018","unstructured":"Clark P, Denova-Guti\u00e9rrez E, Zerbini C, Sanchez A, Messina O, Jaller JJ, Campusano C, Orces CH, Riera G, Johansson H, Kanis JA (2018) FRAX-based intervention and assessment thresholds in seven Latin American countries. Osteoporos Int 29:707\u2013715. https:\/\/doi.org\/10.1007\/s00198-017-4341-4","journal-title":"Osteoporos Int"},{"key":"2219_CR34","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"2219_CR35","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis (in eng). Osteoporos Int 25:2359\u20132381. https:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"2219_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","volume":"19","author":"ANA Tosteson","year":"2008","unstructured":"Tosteson ANA, Melton LJ, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437\u2013447. https:\/\/doi.org\/10.1007\/s00198-007-0550-6","journal-title":"Osteoporos Int"},{"key":"2219_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12020-013-0076-y","volume":"45","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195\u2013197. https:\/\/doi.org\/10.1007\/s12020-013-0076-y","journal-title":"Endocrine"},{"key":"2219_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary. Arch Osteoporos 7:3\u201320. https:\/\/doi.org\/10.1007\/s11657-012-0109-9","journal-title":"Arch Osteoporos"},{"key":"2219_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","volume":"62","author":"J Compston","year":"2009","unstructured":"Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, (NOGG) NOGG, (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK (in eng). Maturitas 62:105\u2013108. https:\/\/doi.org\/10.1016\/j.maturitas.2008.11.022","journal-title":"Maturitas"},{"key":"2219_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N (2017) UK clinical guideline for the prevention and treatment of osteoporosis (in eng). Arch Osteoporos 12:43. https:\/\/doi.org\/10.1007\/s11657-017-0324-5","journal-title":"Arch Osteoporos"},{"key":"2219_CR41","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Mccloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX\u00ae\u2014assessment and intervention thresholds for the UK. Osteoporos Int 19:1395\u20131408. https:\/\/doi.org\/10.1007\/s00198-008-0712-1","journal-title":"Osteoporos Int"},{"key":"2219_CR42","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/bf01623782","volume":"7","author":"JA Kanis","year":"1997","unstructured":"Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390\u2013406. https:\/\/doi.org\/10.1007\/bf01623782","journal-title":"Osteoporos Int"},{"key":"2219_CR43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00198-011-1864-y","volume":"23","author":"H Johansson","year":"2012","unstructured":"Johansson H, Kanis JA, Oden A, Compston J, Mccloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907\u2013915. https:\/\/doi.org\/10.1007\/s00198-011-1864-y","journal-title":"Osteoporos Int"},{"key":"2219_CR44","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00198-015-3176-0","volume":"26","author":"E Mccloskey","year":"2015","unstructured":"Mccloskey E, Kanis JA, Johansson H, Harvey N, Od\u00e9n A, Cooper A, Cooper C, Francis RM, Reid DM, Marsh D, Selby P, Thompson F, Hewitt S, Compston J (2015) FRAX-based assessment and intervention thresholds\u2014an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091\u20132099. https:\/\/doi.org\/10.1007\/s00198-015-3176-0","journal-title":"Osteoporos Int"},{"key":"2219_CR45","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, Mccloskey EV (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. Osteoporos Int 32:1951\u20131960. https:\/\/doi.org\/10.1007\/s00198-021-05942-2","journal-title":"Osteoporos Int"},{"key":"2219_CR46","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jbmr.3163","volume":"32","author":"EV Mccloskey","year":"2017","unstructured":"Mccloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA (2017) The effect of abaloparatide-sc on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res 32:1625\u20131631. https:\/\/doi.org\/10.1002\/jbmr.3163","journal-title":"J Bone Miner Res"},{"key":"2219_CR47","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","volume":"47","author":"JA Kanis","year":"2010","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX (in eng). Bone 47:729\u2013735. https:\/\/doi.org\/10.1016\/j.bone.2010.06.009","journal-title":"Bone"},{"key":"2219_CR48","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s00198-015-3173-3","volume":"26","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Kanis JA, Od\u00e9n A, Burge RT, Mitlak BH, Johansson H, Mccloskey EV (2015) FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporos Int 26:2677\u20132684. https:\/\/doi.org\/10.1007\/s00198-015-3173-3","journal-title":"Osteoporos Int"},{"key":"2219_CR49","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00198-015-3129-7","volume":"26","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Kanis JA, Od\u00e9n A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H, Mccloskey EV (2015) Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int 26:2347\u20132353. https:\/\/doi.org\/10.1007\/s00198-015-3129-7","journal-title":"Osteoporos Int"},{"key":"2219_CR50","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/jbmr.1625","volume":"27","author":"MG Donaldson","year":"2012","unstructured":"Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the fracture intervention trial. J Bone Miner Res 27:1804\u20131810. https:\/\/doi.org\/10.1002\/jbmr.1625","journal-title":"J Bone Miner Res"},{"key":"2219_CR51","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s00198-022-06483-y","volume":"33","author":"M Lorentzon","year":"2022","unstructured":"Lorentzon M, Johansson H, Harvey NC, Liu E, Vandenput L, Crandall CJ, Cauley JA, Leboff MS, Mccloskey EV, Kanis JA (2022) Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability\u2014results from the Women\u2019s Health initiative hormone therapy trials. Osteoporos Int 33:2297\u20132305. https:\/\/doi.org\/10.1007\/s00198-022-06483-y","journal-title":"Osteoporos Int"},{"key":"2219_CR52","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00198-010-1474-0","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, Mccloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX\u00ae. Osteoporos Int 22:2347\u20132355. https:\/\/doi.org\/10.1007\/s00198-010-1474-0","journal-title":"Osteoporos Int"},{"key":"2219_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","volume":"20","author":"EV Mccloskey","year":"2009","unstructured":"Mccloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811\u2013817. https:\/\/doi.org\/10.1007\/s00198-008-0786-9","journal-title":"Osteoporos Int"},{"key":"2219_CR54","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV Mccloskey","year":"2012","unstructured":"Mccloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480\u20131486. https:\/\/doi.org\/10.1002\/jbmr.1606","journal-title":"J Bone Miner Res"},{"key":"2219_CR55","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX (in eng). Bone 44:1049\u20131054. https:\/\/doi.org\/10.1016\/j.bone.2009.02.014","journal-title":"Bone"},{"key":"2219_CR56","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00198-020-05815-0","volume":"32","author":"EV Mccloskey","year":"2021","unstructured":"Mccloskey EV, Johansson H, Harvey NC, Lorentzon M, Shi Y, Kanis JA (2021) Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int 32:1601\u20131608. https:\/\/doi.org\/10.1007\/s00198-020-05815-0","journal-title":"Osteoporos Int"},{"key":"2219_CR57","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00223-015-0092-4","volume":"98","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Compston J, Cooper C, Harvey NC, Johansson H, Od\u00e9n A, Mccloskey EV (2016) SIGN guidelines for Scotland: BMD versus FRAX versus QFracture. Calcif Tissue Int 98:417\u2013425. https:\/\/doi.org\/10.1007\/s00223-015-0092-4","journal-title":"Calcif Tissue Int"},{"key":"2219_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40520-019-01432-y","volume":"32","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD, Mccloskey EV (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32:187\u2013196. https:\/\/doi.org\/10.1007\/s40520-019-01432-y","journal-title":"Aging Clin Exp Res"},{"key":"2219_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-019-0613-2","author":"P Chotiyarnwong","year":"2019","unstructured":"Chotiyarnwong P, Harvey NC, Johansson H, Liu E, Lorentzen M, Kanis JA, Mccloskey EV (2019) Temporal changes in access to FRAX\u00ae in Thailand between 2010 and 2018. Arch Osteoporos. https:\/\/doi.org\/10.1007\/s11657-019-0613-2","journal-title":"Arch Osteoporos"},{"key":"2219_CR60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00198-020-05542-6","volume":"32","author":"EV Mccloskey","year":"2021","unstructured":"Mccloskey EV, Harvey NC, Johansson H, Lorentzon M, Vandenput L, Liu E, Kanis JA (2021) Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporos Int 32:39\u201346. https:\/\/doi.org\/10.1007\/s00198-020-05542-6","journal-title":"Osteoporos Int"},{"key":"2219_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-022-01117-6","author":"P Chotiyarnwong","year":"2022","unstructured":"Chotiyarnwong P, Mccloskey EV, Harvey NC, Lorentzon M, Prieto-Alhambra D et al (2022) Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology\/Quality of Life Working Group. Arch Osteoporos. https:\/\/doi.org\/10.1007\/s11657-022-01117-6","journal-title":"Arch Osteoporos"},{"key":"2219_CR62","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00198-011-1876-7","volume":"23","author":"L Shepstone","year":"2012","unstructured":"Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, Heawood A, Peters TJ, O\u2019Neill T, Torgerson D, Holland R, Howe A, Marshall T, Kanis JA, Mccloskey E (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int 23:2507\u20132515. https:\/\/doi.org\/10.1007\/s00198-011-1876-7","journal-title":"Osteoporos Int"},{"key":"2219_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bone.2004.08.018","volume":"36","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, J\u00f6nsson B (2005) Intervention thresholds for osteoporosis in the UK (in eng). Bone 36:22\u201332. https:\/\/doi.org\/10.1016\/j.bone.2004.08.018","journal-title":"Bone"},{"key":"2219_CR64","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/s0140-6736(17)32640-5","volume":"391","author":"L Shepstone","year":"2018","unstructured":"Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R et al (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. The Lancet 391:741\u2013747. https:\/\/doi.org\/10.1016\/s0140-6736(17)32640-5","journal-title":"The Lancet"},{"key":"2219_CR65","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/jbmr.3411","volume":"33","author":"E Mccloskey","year":"2018","unstructured":"Mccloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, Harvey I, Howe A, Cooper C, Clarke S, Gittoes N, Heawood A, Holland R, Marshall T, O\u2019Neill TW, Peters TJ, Redmond N, Torgerson D, Kanis JA (2018) Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res 33:1020\u20131026. https:\/\/doi.org\/10.1002\/jbmr.3411","journal-title":"J Bone Miner Res"},{"key":"2219_CR66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00198-019-05142-z","volume":"31","author":"CM Parsons","year":"2020","unstructured":"Parsons CM, Harvey N, Shepstone L, Kanis JA, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I, Holland R, Redmond NM, Howe A, Marshall T, Peters TJ, Torgerson D, O\u2019Neill TW, Mccloskey E, Cooper C (2020) Systematic screening using FRAX\u00ae leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int 31:67\u201375. https:\/\/doi.org\/10.1007\/s00198-019-05142-z","journal-title":"Osteoporos Int"},{"key":"2219_CR67","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00198-020-05372-6","volume":"31","author":"E S\u00f6reskog","year":"2020","unstructured":"S\u00f6reskog E, Borgstr\u00f6m F, Shepstone L, Clarke S, Cooper C, Harvey I, Harvey NC, Howe A, Johansson H, Marshall T, O\u2019Neill TW, Peters TJ, Redmond NM, Turner D, Holland R, Mccloskey E, Kanis JA (2020) Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporos Int 31:1499\u20131506. https:\/\/doi.org\/10.1007\/s00198-020-05372-6","journal-title":"Osteoporos Int"},{"key":"2219_CR68","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jbmr.3381","volume":"33","author":"DA Turner","year":"2018","unstructured":"Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, Harvey NC, Holland R, Howe A, Mccloskey E, O\u2019Neill TW, Torgerson D, Fordham R (2018) The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP Study. J Bone Miner Res 33:845\u2013851. https:\/\/doi.org\/10.1002\/jbmr.3381","journal-title":"J Bone Miner Res"},{"key":"2219_CR69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00223-014-9950-8","volume":"96","author":"KH Rubin","year":"2015","unstructured":"Rubin KH, Holmberg T, Rothmann MJ, H\u00f8iberg M, Barkmann R, Gram J, Hermann AP, Bech M, Rasmussen O, Gl\u00fcer CC, Brixen K (2015) The Risk-Stratified Osteoporosis Strategy Evaluation study (ROSE): a randomized prospective population-based study. design and baseline characteristics. Calcif Tissue Int 96:167\u2013179. https:\/\/doi.org\/10.1007\/s00223-014-9950-8","journal-title":"Calcif Tissue Int"},{"key":"2219_CR70","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","volume":"29","author":"KH Rubin","year":"2018","unstructured":"Rubin KH, Rothmann MJ, Holmberg T, H\u00f8iberg M, M\u00f6ller S, Barkmann R, Gl\u00fcer CC, Hermann AP, Bech M, Gram J, Brixen K (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29:567\u2013578. https:\/\/doi.org\/10.1007\/s00198-017-4326-3","journal-title":"Osteoporos Int"},{"key":"2219_CR71","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/jbmr.3815","volume":"34","author":"T Merlijn","year":"2019","unstructured":"Merlijn T, Swart KM, Schoor NM, Heymans MW, Zwaard BC, Heijden AA, Rutters F, Lips P, Horst HE, Niemeijer C, Netelenbos JC, Elders PJ (2019) The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res 34:1993\u20132000. https:\/\/doi.org\/10.1002\/jbmr.3815","journal-title":"J Bone Miner Res"},{"key":"2219_CR72","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-019-05226-w","volume":"31","author":"T Merlijn","year":"2020","unstructured":"Merlijn T, Swart KMA, Van Der Horst HE, Netelenbos JC, Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31:251\u2013257. https:\/\/doi.org\/10.1007\/s00198-019-05226-w","journal-title":"Osteoporos Int"},{"key":"2219_CR73","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, Mccloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816. https:\/\/doi.org\/10.1007\/s00198-010-1524-7","journal-title":"Osteoporos Int"},{"key":"2219_CR74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jocd.2011.05.010","volume":"14","author":"T Masud","year":"2011","unstructured":"Masud T, Binkley N, Boonen S, Hannan MT, Members FPDC (2011) Official positions for FRAX\u00ae clinical regarding falls and frailty: can falls and frailty be used in FRAX\u00ae? from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAX\u00ae (in eng). J Clin Densitom 14:194\u2013204. https:\/\/doi.org\/10.1016\/j.jocd.2011.05.010","journal-title":"J Clin Densitom"},{"key":"2219_CR75","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00198-022-06550-4","volume":"33","author":"JA Kanis","year":"2022","unstructured":"Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, Mccloskey EV (2022) Adjusting conventional FRAX estimates of fracture probability according to the number of prior fractures. Osteoporos Int 33:2507\u20132515. https:\/\/doi.org\/10.1007\/s00198-022-06550-4","journal-title":"Osteoporos Int"},{"key":"2219_CR76","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00198-019-05106-3","volume":"30","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, Mccloskey EV, Johansson H, Harvey NC, Kanis JA (2019) Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. Osteoporos Int 30:2195\u20132203. https:\/\/doi.org\/10.1007\/s00198-019-05106-3","journal-title":"Osteoporos Int"},{"key":"2219_CR77","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00198-020-05517-7","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, Mccloskey EV (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 31:1817\u20131828. https:\/\/doi.org\/10.1007\/s00198-020-05517-7","journal-title":"Osteoporos Int"},{"key":"2219_CR78","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00198-010-1461-5","volume":"22","author":"WD Leslie","year":"2011","unstructured":"Leslie WD, Lix LM, Johansson H, Oden A, Mccloskey E, Kanis JA (2011) Spine\u2013hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839\u2013847. https:\/\/doi.org\/10.1007\/s00198-010-1461-5","journal-title":"Osteoporos Int"},{"key":"2219_CR79","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00223-014-9911-2","volume":"95","author":"H Johansson","year":"2014","unstructured":"Johansson H, Kanis JA, Od\u00e9n A, Leslie WD, Fujiwara S, Gl\u00fcer CC, Kroger H, Lacroix AZ, Lau E, Melton LJ, Eisman JA, O\u2019Neill TW, Goltzman D, Reid DM, Mccloskey E (2014) Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int 95:428\u2013435. https:\/\/doi.org\/10.1007\/s00223-014-9911-2","journal-title":"Calcif Tissue Int"},{"key":"2219_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00223-015-9980-x","volume":"96","author":"EV Mccloskey","year":"2015","unstructured":"Mccloskey EV, Od\u00e9n A, Harvey NC, Leslie WD, Hans D, Johansson H, Kanis JA (2015) Adjusting fracture probability by trabecular bone score. Calcif Tissue Int 96:500\u2013509. https:\/\/doi.org\/10.1007\/s00223-015-9980-x","journal-title":"Calcif Tissue Int"},{"key":"2219_CR81","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jocd.2015.07.004","volume":"19","author":"WD Leslie","year":"2016","unstructured":"Leslie WD, Lix LM, Morin SN, Johansson H, Od\u00e9n A, McCloskey EV, Kanis JA (2016) Adjusting hip fracture probability in men and women using hip axis length: the manitoba bone density database (in eng). J Clin Densitom 19:326\u2013331. https:\/\/doi.org\/10.1016\/j.jocd.2015.07.004","journal-title":"J Clin Densitom"},{"key":"2219_CR82","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/jbmr.3538","volume":"33","author":"WD Leslie","year":"2018","unstructured":"Leslie WD, Johansson H, Mccloskey EV, Harvey NC, Kanis JA, Hans D (2018) Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD registry. J Bone Miner Res 33:1923\u20131930. https:\/\/doi.org\/10.1002\/jbmr.3538","journal-title":"J Bone Miner Res"},{"key":"2219_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116651","author":"M Schini","year":"2022","unstructured":"Schini M, Bhatia P, Shreef H, Johansson H, Harvey NC, Lorentzon M, Kanis JA, Bandman O, McCloskey EV (2022) Increased fracture risk in Parkinson\u2019s disease-an exploration of mechanisms and consequences for fracture prediction with FRAX (in eng). Bone. https:\/\/doi.org\/10.1016\/j.bone.2022.116651","journal-title":"Bone"},{"key":"2219_CR84","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00198-015-3180-4","volume":"26","author":"H Johansson","year":"2015","unstructured":"Johansson H, Od\u00e9n A, Lorentzon M, Mccloskey E, Kanis JA, Harvey NC, Karlsson MK, Mellstr\u00f6m D (2015) Is the Swedish FRAX model appropriate for Swedish immigrants? Osteoporos Int 26:2617\u20132622. https:\/\/doi.org\/10.1007\/s00198-015-3180-4","journal-title":"Osteoporos Int"},{"key":"2219_CR85","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/1753-6405.12063","volume":"37","author":"SL Brennan","year":"2013","unstructured":"Brennan SL, Williams LJ, Berk M, Pasco JA (2013) Socioeconomic status and quality of life in population-based Australian men: data from the geelong osteoporosis study (in eng). Aust N Z J Public Health 37:226\u2013232. https:\/\/doi.org\/10.1111\/1753-6405.12063","journal-title":"Aust N Z J Public Health"},{"key":"2219_CR86","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jbmr.1582","volume":"27","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Lix LM, Johansson H, Oden A, Mccloskey E, Kanis JA (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243\u20131251. https:\/\/doi.org\/10.1002\/jbmr.1582","journal-title":"J Bone Miner Res"},{"key":"2219_CR87","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1002\/jbmr.2280","volume":"29","author":"WD Leslie","year":"2014","unstructured":"Leslie WD, Orwoll ES, Nielson CM, Morin SN, Majumdar SR, Johansson H, Od\u00e9n A, Mccloskey EV, Kanis JA (2014) Estimated lean mass and fat mass differentially affect femoral bone density and strength index but are not FRAX independent risk factors for fracture. J Bone Miner Res 29:2511\u20132519. https:\/\/doi.org\/10.1002\/jbmr.2280","journal-title":"J Bone Miner Res"},{"key":"2219_CR88","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00198-022-06435-6","volume":"33","author":"L Vandenput","year":"2022","unstructured":"Vandenput L, Johansson H, Mccloskey EV, Liu E, \u00c5kesson KE et al (2022) Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporos Int 33:2103\u20132136. https:\/\/doi.org\/10.1007\/s00198-022-06435-6","journal-title":"Osteoporos Int"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02219-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02219-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02219-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:31:41Z","timestamp":1709227901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02219-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02219-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS: no conflicts of interest in relation to this study. HJ: no conflicts of interest in relation to this study. NCH: reports personal fees, consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, and Internis Pharma, outside the submitted work. ML has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. JAK: Director, Osteoporosis Research Ltd. EVM: Director, Osteoporosis Research Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All individual cohorts used in the development of FRAX and FRAXplus have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield. Participant data are stored in coded, de-identified form. Only summary statistics and aggregate data are published, not allowing for identification of individual study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Neither FRAX nor FRAXplus involve the use of animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Informed consent has been obtained from all study participants contributing to the development of FRAX and FRAXplus.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}